GlassScriptPhysician profile
Christopher A Thompson
NPI 1952399305
$14,315.89
in general payments reported to CMS, 2019-2025
24 companies · $93.05 in 2025
The $93.05 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $1,554 · 2021: $4,417 · 2022: $7,651 · 2023: $233 · 2024: $61.57 · 2025: $93.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $7,011.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $5,552.06 | 2020-2021 | |
| Abbvie INC. | $482.93 | 2019-2023 | Lo Loestrin Fe |
| Medical Device Business Services, INC. | $325.00 | 2022 | |
| Astellas Pharma US INC | $223.81 | 2019-2025 | Veozah, Myrbetriq |
| Myriad Women'S Health, INC. | $115.81 | 2023 | Myrisk |
| Celgene Corporation | $78.23 | 2019 | |
| Daiichi Sankyo INC. | $71.75 | 2019-2021 | |
| Therapeuticsmd, INC. | $69.08 | 2019-2022 | |
| Hologic Sales and Service, LLC | $58.82 | 2019-2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Avion Pharmaceuticals | $57.51 | 2019-2021 | |
| Exeltis, USA INC. | $38.62 | 2024-2025 | Slynd |
| Pfizer INC. | $31.64 | 2019-2025 | |
| Minerva Surgical, INC | $30.71 | 2022 | |
| Amag Pharmaceuticals, INC. | $26.56 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $24.72 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.67 | 2019-2020 | |
| Evofem Biosciences, INC. | $20.58 | 2024 | |
| Novo Nordisk INC | $15.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2019 | |
| Intra-Sana Laboratories | $14.97 | 2022 | |
| Sanofi Pasteur INC. | $14.68 | 2019 | |
| Shield Therapeutics INC | $13.98 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.